GENERIC-DRUG USE FIGURES TO RISE SHARPLY IN EUROPE

SEPTEMBER 01, 2007

The appetite for generic drugs throughout the European Community is expected to double in the next 7 years, jumping from $17.18 billion in 2006 to nearly $36 billion by 2013, according to a new market analysis by Frost & Sullivan. As in the United States, rising health costs in Europe are causing government leaders to explore methods for promoting increased use of more cost-effective generic medicines, the study noted.

?Patent expiries, pro-generic reforms in certain countries, and need for cheap, effective medicines are the key factors driving growth in the European generics market,? a researcher for the company explained. ?Various studies have indicated the cost savings obtained from generics, and several governments in Europe are actively promoting generics.?



SHARE THIS SHARE THIS
0
 

In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine

Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.


 

 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.